Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,512.38 -3.89 -0.03%
TOPIX 1,171.40 -1.97 -0.17%
HANG SENG 22,760.24 64.23 0.28%

Amarin and Forest Laboratories Under Review: Drug Makers Face Growing Generic Competition



Amarin and Forest Laboratories Under Review: Drug Makers Face Growing Generic
                                 Competition

  PR Newswire

  LONDON, February 15, 2013

LONDON, February 15, 2013 /PRNewswire/ --

Last year saw the expiration of patents for several blockbuster drugs ,
leading to increasing generic competition. The trend is expected to continue
in 2013 , with patents on a number of blockbuster drugs set to expire. For
drug manufacturers , intensifying generic competition is a major concern.
Meanwhile , companies such as Amarin Corporation Plc (ADR) (NASDAQ: AMRN) and
Forest Laboratories Inc. (NYSE: FRX) are also assessing the impact of
President Obama's Affordable Care Act (ACA). StockCall has released free
charting and technical research on these two aforementioned companies.
Register to read these reports at

http://www.stockcall.com/report  

Generic Competition

Generic competition is a major concern for major pharmaceutical companies as
well as biotechnology firms. Earlier this month, Merck & Co. had reported a 7%
drop in its fourth quarter profit due to hits from generic competition.

With several blockbuster drugs set to see their patents expire this year, the
competition from generic drugs is expected to intensify. Generic competition
is expected to erode billions of dollars from major pharmaceutical and
biotechnology companies' annual sales. The key for big pharmaceutical
companies, as well as for companies such as Amarin Corporation Plc and Forest
Laboratories Inc., will be to make investments in new drug discovery and
development and create a strong pipeline of products.

Impact of Affordable Care Act (ACA)

Another major development in the pharmaceutical industry has been the
Affordable Care Act (ACA). The U.S. Supreme Court last year upheld the ACA and
the healthcare industry is now preparing for sweeping changes that will hit
the industry.

While the ACA has its critics, the reform could ultimately benefit drug
manufacturers as the increase in the number of insured individuals will boost
sales. In the near-term though, the reform may lead to higher costs for
companies.

Amarin Corporation Plc Issued Notice of Allowance by USPTO

Earlier this week, Amarin Corporation Plc, which focuses on the
commercialization and development of therapeutics to improve cardiovascular
health, said that the United States Patent and Trademark Office (USPTO)
published notification of Notice of Allowance for U.S. Patent Application
Serial Number 13/614,129. The patent is related to Vascepa®, which is the
company's first FDA approved product. Sign up for the free report on Amarin
Corporation plc at

http://www.StockCall.com/AMRN021513.pdf  

Last month, Amarin Corporation Plc announced that Vascepa capsules, a therapy
for patients in the U.S. to treat severe hypertriglyceridemia, is available by
way of physician prescription.

Joseph Zakrzewski, Chairman and CEO of Amarin Corporation Plc, said that the
company has worked closely with leading clinical experts and regulatory
authorities to bring the important new prescription pure-EPA omega-3 therapy
to patients with very high triglycerides.

Forest Laboratories Inc.'s Q3 Results

Last month, Forest Laboratories Inc. reported its financial results for the
third quarter of fiscal 2013. The company's GAAP loss per share for the
quarter was $0.58. Net sales for the quarter were $678 million. Forest
Laboratories Inc. free technical report can be accessed by signing up at

http://www.StockCall.com/FRX021513.pdf  

Howard Solomon, Chairman and CEO of Forest Laboratories Inc., last month, said
that in the third quarter of fiscal 2013, as expected, the company incurred a
loss resulting principally from sales lost following the expiration of
Lexapro's patent exclusivity in March 2012. Solomon, however, noted that the
company launched two new products in December 2012 and believes that the sales
of these products, and the seven products already launched, will ultimately
equal and exceed the sales lost following the expiration of Lexapro's
exclusivity.

About StockCall.com

StockCall.com is a financial website where investors can have easy, precise
and comprehensive research and opinions on stocks making the headlines. Sign
up today to talk to our financial analyst at

http://www.stockcall.com  

Contact: Contact Person:William T. Knight, Email: info@stockcall.com , Contact
Number: +1-(646)-396-9857 (9:00 am EST - 01:30 pm EST)
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement